Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined th...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell
Auteurs principaux: Wec, Anna Z., Herbert, Andrew S., Murin, Charles D., Nyakatura, Elisabeth K., Abelson, Dafna M., Fels, J. Maximilian, He, Shihua, James, Rebekah M., de La Vega, Marc-Antoine, Zhu, Wenjun, Bakken, Russell R., Goodwin, Eileen, Turner, Hannah L., Jangra, Rohit K., Zeitlin, Larry, Qiu, Xiangguo, Lai, Jonathan R., Walker, Laura M., Ward, Andrew B., Dye, John M., Chandran, Kartik, Bornholdt, Zachary A.
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808922/
https://ncbi.nlm.nih.gov/pubmed/28525755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cell.2017.04.037
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires